24849-51-2

Upstream product

• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 

Downstream Products

• 23821-75-2 [4-(4-methoxy-phenyl)-2-o-tolyl-thiazol-5-yl]-acetic acid 
• 89402-83-5 [2-(6-Fluoro-benzothiazol-2-ylamino)-4-(4-methoxy-phenyl)-thiazol-5-yl]-acetic acid 
• 89402-77-7 [2-(Benzothiazol-2-ylamino)-4-(4-methoxy-phenyl)-thiazol-5-yl]-acetic acid 
• 89402-80-2 [2-(6-Chloro-benzothiazol-2-ylamino)-4-(4-methoxy-phenyl)-thiazol-5-yl]-acetic acid 
• 89402-73-3 {4-(4-Methoxy-phenyl)-2-[4-(4-methoxy-phenyl)-thiazol-2-ylamino]-thiazol-5-yl}-acetic acid 
• 1214888-47-7 C₂₄H₁₉NO₄S 
• 1214888-56-8 C₁₉H₁₆ClNO₃S 
• 23821-59-2 [4-(4-methoxy-phenyl)-2-phenyl-thiazol-5-yl]-acetic acid 
• 89402-89-1 [2-(6-Methoxy-benzothiazol-2-ylamino)-4-(4-methoxy-phenyl)-thiazol-5-yl]-acetic acid 
• 89402-67-5 [4-(4-Methoxy-phenyl)-2-(4-phenyl-thiazol-2-ylamino)-thiazol-5-yl]-acetic acid 
• 89402-70-0 [2-[4-(4-Chloro-phenyl)-thiazol-2-ylamino]-4-(4-methoxy-phenyl)-thiazol-5-yl]-acetic acid 
• 89402-86-8 [4-(4-Methoxy-phenyl)-2-(6-methyl-benzothiazol-2-ylamino)-thiazol-5-yl]-acetic acid 
• 23821-66-1 [2-(4-chloro-phenyl)-4-(4-methoxy-phenyl)-thiazol-5-yl]-acetic acid 
• 23821-74-1 [2,4-bis-(4-methoxy-phenyl)-thiazol-5-yl]-acetic acid 

Relevant academic research and scientific papers

INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE

Compounds and salts thereof which are acyl-sulfonamides or certain carboxylic acids and which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include 2-aminothiazoles and triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 2-amino and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.

Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1

Structure-activity relationships of three related series of 4-phenylthiazol-5-ylacetic acids, derived from two hits emanating from a focused library obtained by in silico screening, have been explored as CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) antagonists. Several compounds with double digit nanomolar binding affinity and full antagonistic efficacy for human CRTH2 receptor were obtained in all subclasses. The most potent compound was [2-(4-chloro-benzyl)-4-(4-phenoxy-phenyl)-thiazol-5-yl]acetic acid having an binding affinity of 3.7 nM and functional antagonistic effect of 66 nM in a BRET and 12 nM in a cAMP assay with no functional activity for the other PGD2 DP receptor (27 μM in cAMP).